Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma

Published:2013-07-04 Issue:3 Volume:30 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Abdel-Rahman Omar,Abdel-Wahab Manal,Shaker Mohammed,Abdel-Wahab Sherif,Elbassiony Mohammed,Ellithy Mahmoud

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-013-0655-z.pdf

Reference18 articles.

1. Graham J, Newman D, Smirniotopolous D, et al. Transplantation for hepatocellular carcinoma in younger patients has an equivocal survival advantage as compared with resection. Transpl Proc. 2013;45(1):265–71.

2. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

3. Llovet M, Ricci R, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

4. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–30.

5. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf , Accessed on 5 June 2013.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care;Digestive and Liver Disease;2024-09

2. Transcriptional elongation control of hypoxic response;Proceedings of the National Academy of Sciences;2024-04-02

3. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma;BMB Reports;2022-11-30

4. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma;Hepatic Oncology;2022-03

5. Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials;Gastrointestinal Tumors;2021-12-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3